---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003939"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:19:52.095315+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics details 2024 clinical milestones; STK-001 data in Q1, STK-002 trial in UK

## Summary
- In Q1 2024, plans to report safety, PK, and CSF results from 81 patients in STK-001 Phase 1/2a and OLE studies.
- Seizure frequency data from ~20 patients who received 1-3 doses of 70mg STK-001, followed for six months, will be released in Q1.
- Repeat dose effects (30mg, 45mg) on seizure frequency and cognition/behavior from OLE studies also expected in Q1.
- Depending on Q1 results, plans to start Phase 3 preparation including regulatory discussions and toxicology data.
- Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy expected to begin in UK in 2024.

## SEC filing metadata
- accession: 0001193125-24-003939
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312524003939/0001193125-24-003939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312524003939/d39993d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003939
- JSON: https://secwatch.observer/filing/0001193125-24-003939.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003939.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.